坦辛IIA对尿路状况下的内皮细胞功能障碍的影响
Li-Hua Wang1, Bo Yang2, Zhe Wang1
1Department of Kidney Disease and Blood Purification Center, 2nd Hospital of Tianjin Medical University, Tianjin, China.
Journal of biochemical and molecular toxicology
|July 25, 2024
概括
坦西诺IIA可以通过向Caveolin-1/ERK1/2通路来改善血液透析的尿素患者的内皮细胞功能,从而潜在地预防动脉静脉囊功能障碍.
科学领域:
- 心血管生物学 心血管生物学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉静脉 (AVF) 对于血液透析至关重要,但容易出现功能障碍.
- 导致狭窄的静脉新极限增生是AVF衰竭的主要原因.
- 在尿性条件下的内皮细胞 (EC) 功能障碍有助于AVF不成熟.
研究的目的:
- 调查Tanshinone IIA在尿素条件和剪切应力下对ECs的影响.
- 阐明Tanshinone IIA调节EC功能的分子机制.
- 评估Tanshinone IIA在尿性血管接入功能障碍方面的治疗潜力.
主要方法:
- 人类ECs在模拟尿素状况和剪切压力下用坦辛IIA硫酸盐 (STS) 治疗.
- 分析了NF-κB p65,JNK,原I,ERK1/2和Caveolin-1的表达水平.
- 使用抑制和上调策略来确认途径的参与.
主要成果:
- 在尿血引起的EC中,STS治疗降低了NF-κB p65,JNK和原I的表达.
- 抑制ERK1/2和高调 Caveolin-1 增强了 STS 对这些标记物的抑制作用.
- STS证明了对ECs的保护作用,防止尿血引起的功能障碍.
结论:
- 坦辛IIA通过STS可以通过调节Caveolin-1/ERK1/2通路来改善尿血中的EC功能.
- 这种途径调节导致NF-κB p65,JNK和原I等益增多性因子的表达减少.
- 坦辛IIA为预防血液透析患者的AVF不成熟和功能障碍提供了一个有前途的治疗候选药物.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
589
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
589
01:23Antihypertensive Drugs: Vasodilators
495
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
495